

DEPLOYMENT OF ACTIVE VACCINE CARRIER FOR LAST-MILE COLD CHAIN DELIVERY OF COVID-19 VACCINES IN ASSAM

PROJECT IMPACT REPORT 2021 - 2022

HOST ORGANISATION



Centre for Cellular and Molecular Platforms



Office of the Principal Scientific Adviser to the Government of India



ACKNOWLEDGEMENTS

Directorate of Health Services (FW), Assam



LEFT BLANK INTENTIONALLY

Copyright © 2022 – Centre for Cellular & Molecular Platforms (C-CAMP)

All rights reserved. Printed in India. No part of this report may be used or reproduced in any form or by any means, or stored in a database or retrieval system, without prior written permission of the company. Making copies of any part of this document for any purpose other than your own personal use is a violation of India copyright laws.



REPORT SUMMARY

The purpose of this project was to introduce **a new cold-chain technology – an Active Vaccine Carrier**, by the name of Emvolio to certain states amidst the COVID-19 pandemic. Incubated and enabled by Centre for Cellular and molecular Platforms (C-CAMP), the Emvolio Active Vaccine Carrier was manufactured by Blackfrog Technologies, and scaled to deploy and support public health facilities in Assam and Manipur.

This report is a concise description of the **implementation**, **impact and the future implication** of adopting Emvolio active vaccine carrier for integration with public health sectors.

- 50 Emvolio Vaccine Carriers were deployed in 6 districts, with a distribution of 5 devices per PHCs
- Cold-Chain Technicians and healthcare workers (Auxiliary nurse midwife ANMs) were successfully trained on the utilisation of these new devices.
- Initial adoption challenges included administrative schedules, apprehension towards technology and reluctance to try something new even if better and more efficient.
- Need for a solar-powered, portable, battery-operated vaccine carrier was strongly established based on the field surveys conducted by C-CAMP.
- Common challenges faced by ANMs in the field included poor connectivity, remote areas, intermittent or no electrical supply and limitations for long outreach programs.
- Need for new vaccination and immunization protocol proposed in case study section

The Emvolio Active Vaccine Carrier addresses the following needs in the field –

- Poor or no electrical supply it is compatible with solar
- Strict temperatures of 2 to 8 °C across drastic ambient temperatures
- Efficient management through IoT -based technology
- Temperature monitoring without data loggers
- Portability in difficult terrains
- Weatherproofing to meet the diverse climate across Indian regions
- Easy to operate, positive end-user training and capacity building
- Scaled-down routine and operating protocol for maintenance of vaccine carriers
- Multi-functional beyond COVID-19 Capacity for multiple types of biological samples and specimens, routine immunization, and so on.


In conclusion, the deployment was successful and the mark of disruptive innovation in public health system strengthening. The adoption of a validated, impact-driven, technology solution like Active Vaccine Carrier is achieved through the support of public health authorities. This is required to enable successful integration of innovation in to public health facilities. This is critical for the improvement in health outcomes, including moving the needle towards better indicators in Maternal Child healthcare.





Contents

REPORT SUMMARY	3
Contents	4
Project Summary	6
Background	7
Project Stakeholders	8
Technology Access Model for Assam	11
Impact Overview	12
Impact Numbers	13
Impact in Images	14
C-CAMP Programme Expertise	16
Innovation	16
Implementation & Impact Partner	16
Mentorship & Incubation	17
Hand holding for Industry Access & Network	
Looking Ahead	
Potential Impact Capacity	
Emvolio's Vaccine Surveillance Model	
Meeting SD3 goals through SD7 Energy Model	
Model for Scaling and Deployment of healthcare technology	
Deployment Report	24
Capacity Building	25
Device Monitoring	
Outcomes A snapshot	
Case Study	
Understanding the Cold-Chain System for the development of an Immunization & Vaccination Model for Improved Healthcare	34



With the support and cooperation from Directorate of Health Services & Family Welfare, Guwahati, Assam, 50 units of Blackfrog Technologies' Emvolio Active Vaccine Carrier, are successfully deployed across 6 districts in Assam.







Project Summary

Scaling indigenous health technology for strengthening lastmile vaccine delivery in public health systems in India

AIM

Use of Emvólio Active Vaccine Carrier in last-mile cold chain delivery of COVID-19 vaccines in Assam

KEY OBJECTIVES

- 1. Deployment of 50 units of Emvólio Active Vaccine Carriers
- 2. Training of cold-chain technicians and ANMs
- 3. Impact Monitoring of deployed Emvólio devices

BENEFICIARIES

Assam | Public Health Centers and sub-centres in the Districts of Dhubri, South Salmara, Karbi Anglong, Majuli and Dima Hasao



Background

Through CCAMP's Corporate Social Responsibility (CSR) partner and incubation and acceleration platform an indigenous innovation – portable, battery operated, active vaccine carrier for last-mile safe delivery of COVID-19 vaccines - was selected for rapid deployment in the public health sector in Assam. C-CAMP had conducted due diligence processes for the innovation and technology partners through its ongoing programs, ensuring ready-to-deploy solutions are available when the opportunity to strengthen and support the nation's fight against COVID-19 arises.

Spread across varying terrains and low-resource settings, 11 Public Health Centers (PHCs) across 6 districts, were selected by the Office of Directorate of Health Services & Family Welfare (DHSFW), Guwahati, for the deployment of this innovative technology to strengthen public health infrastructure.

The deployment began in September with the shipment of 50 Emvolio Vaccine Carriers to Directorate of Health Services (Family Welfare) (DHSFW), Guwahati. The Emvolio vaccine carriers were introduced to the state vaccination program in October 2021 with the support and guidance of Mr. Munindranath M. Ngatey (Director); Dr. B. Goswami (Joint-Director (UIP), SEPIO); Dr. BK Choudhury (State Cold Chain Officer. An MoU was signed between the technology partner, Blackfrog Technologies, and DHSFW, Assam, ahead of the commissioning and technology training which took place at the DHSFW office. Project facilitation, implementation and monitoring was taken care by C-CAMP.



Project Plan & Timeline



Project Stakeholders

Guidance & Facilitation | Office of the Principal Scientific Adviser to The Government of India (PSA)

The Office of the PSA provides pragmatic and objective advice to the Prime Minister and cabinet on matters related to science, technology and innovation with a focus on application of science and technology in critical infrastructure, economic and social sectors in partnership with Government departments, institutions and industry. This project would not have been possible without the guidance and facilitation from the Office of the PSA.

Overall Innovation, Incubation & Implementation | Centre for Cellular and Molecular Platforms (C-CAMP)

The Centre for Cellular and Molecular Platforms, or C-CAMP, an initiative supported by the Department of Biotechnology, Govt of India, has been an enabler and catalyst of cutting-edge research and innovation in the life sciences since 2009. As a part of C-CAMP's mandate of promoting entrepreneurship and innovation, C-CAMP has created and fostered an entrepreneur-friendly culture in and around Academic/Research environment through its involvement in Seed Funding Schemes for Startups, Entrepreneur Mentorship program and Bio-Incubation facility.

As an organisation dedicated to the service of the nation, C-CAMP is dedicated to ensuring that the latest products and services in life sciences impact the lives of any individual in the country regardless of their means. C-CAMP works with several reputed philanthropic agencies to provide interventions, especially in the realm of healthcare, thus enabling cutting-edge innovation to have real on-ground impact. C-CAMP builds precise indigenous innovations based on identification of problems specific to India and its public health sectors, right from primary to tertiary care. C-CAMP's Technology Impact Program receives support from various Corporate Social Responsibility partners to support funding for COVID-19 initiatives and beyond.



Government Partner | Directorate of Health Services (Family Welfare), Guwahati, Assam

The DHS(FW), under the Ministry for Health and Family Welfare, is responsible for maintaining and developing the health care system in the state and guiding and supervising the Health and Family Welfare Programme of the state. The activities of the department include establishment and maintenance of medical institutions with necessary infrastructure, implementation of National Disease Control and Eradication Programmes, Control of communicable as well as non-communicable diseases apart from various other functions.


The office has been playing a pivotal role in the country's fight against the COVID-19 pandemic, rising to the challenge and being a pioneer in facilitating and adopting innovation to combat COVID-19.





Innovation & Technology | Blackfrog Technologies


Emvólio is a portable active cooling (battery-powered) device that will provide a platform for delivery of vaccines and all other biologicals like blood, serums, viral culture which require to be kept strictly between 2°C and 8°C for 12+ hours in the field. The product has been designed in accordance with WHO PQS E003 specifications and conforms to IEC 60601 standards.








Technology Access Model for Assam







EMVOLIO IMPACT NUMBERS



6/9/2020

Carriers

Page 12 of 40

*monthly, per PHC

Project Impact Report | Jan 2022 Copyright © 2022 – Centre for Cellular & Molecular Platforms (C-CAMP)



Impact Numbers

TOTAL IMPACT	Project Mid-Point (Last 3 months)	Potential Estimate for 12 months
Number of people vaccinated against COVID-19 in 6 Districts*	6424+	51,392+
Number of public health centers benefitted by Emvolio	11	26
Number of public health sub - centers potentially benefitted by Emvolio**	232	604
Number of healthcare workers trained on new active vaccine carrier technology	103	1370
No. of hours of cooling capacity provided for vaccines per device	310	1238+
Average storage capacity provided for 10ml vaccine vials per device (Approx. 45 vials carried per session)	3600+ vials	14,400+ vials

*50 Emvolio vaccine carriers distributed across 6 districts. This number reflects total number of doses administered using Emvolio in the last 3 months in 3 out of 6 districts in Assam. Numbers are still being collected for remaining 3 districts. It is expected to be 1.5 times the measured total.

** This reflects total number of sub-centers under the 11 PHCs selected for deployment which Emvolio can be utilised for as per the need.

Preparedness and adoption of any new technology is always critical to receiving the complete benefit envisaged at the time of innovation. C-CAMP with DHSFW, Guwahati, remain committed to working with the manufacturers on increasing access to under-served regions in Assam and supporting the adoption of critical technology in order to scale impact, beyond the pandemic.



Impact in Images









6

Vaccine Carrier Cooling Capacity Created

20,160 + Hrs

For heavy usage for outreach sessions





Project Impact Report | Jan 2022 Copyright © 2022 – Centre for Cellular & Molecular Platforms (C-CAMP)



C-CAMP Programme Expertise

C-CAMP has played an integral role in achieving the milestones outlined for this project and beyond. In addition to comprehensive support for the startup with far-reaching implications, C-CAMP has contributed to the overall ecosystem surrounding innovation for scale and impact in the public health sector.

Innovation |

- C-CAMP's unique position as a technology platform brings to the world, access to innovation through its various programs that create a holistic ecosystem from discovery to innovation to acceleration and now to deployment.
- C-CAMP builds precise indigenous innovations based on identification of problems specific to India and its public health sectors, right from primary to tertiary care.
- C-CAMP nurtures these innovations for far-reaching impact and solving healthcare problems at scale in India. Consequently, the selection of the appropriate and relevant technology partners for this project at the onset of the pandemic was possible through C-CAMP's expertise in the area of innovation.
- C-CAMP had conducted due diligence processes for the innovation and technology partners through its ongoing programs, ensuring ready-to-deploy solutions are available when the opportunity to strengthen and support the nation's fight against COVID-19 arises.

Implementation & Impact Partner |

• C-CAMP's programme and project team have built process and strategy-driven templates for achieving project milestones, with the creation of weekly project level checklists, schedules, and escalation processes for technical issues in deployment and implementation. The team has provided verification for execution, outputs, and outcomes at all stages of the project.

• Facilitating Stakeholder Escalation and engagement by reaching out to different beneficiaries to provide access for deployment.

• Templates for MoUs and public-private partner agreements.

· C-CAMP was responsible for all communication and visibility across the various stakeholders involved in the project.

• Development of the framework for monitoring & evaluation and impact models. From conception to execution for research data collection from the field and continual monitoring through engagement with the beneficiaries.



• Facilitating field-driven research and impact monitoring vertical for the startup as well as for the project. Concept of case-studies was introduced to the startup with a focus on the larger picture and programme has led to access to active feedback from the end-users in the public health system.

Mentorship & Incubation |

• Provided mentorship and handholding for supply chain management, manufacturing scale-up, logistics and monitoring and evaluation of technology usage.

• Hand Holding for deployment, commissioning, and training across the different beneficiaries.

• Project templates from C-CAMP have become part of the company's internal organizational structure and data collection. C-CAMP has supported metrics for building credibility which has in turn led to expansion in marketing strategy and further product proposals.

- Provided incubation support which includes development of business scale-up strategies.
- Engineering inputs from the domain experts for problem-solving and product improvisation.

Hand holding for Industry Access & Network |

• Stepping-stone and platform for networking with a host of stakeholders such as investors, potential customers, and governmental agencies.

• C-CAMP introduced the startup to experts with industrial and academic experience to bring in technical expertise, garner credibility and work towards a roadmap for the startup's future growth.

• Provided access to mentorship for health economic cost benefit analysis for the technology.

• Access to medical experts for detailed review of the product based on their field experience and requirements. This has led to potential improvements for future versions of the product as well as delivery mechanisms in healthcare.

 \cdot Visibility and collateral marketing for the startup and innovation furthering private-public partnerships in the health ecosystem.


• C-CAMP brings a crucial trust factor and human dynamic responsible for facilitating crosslearnings across startups and peer to peer interaction for support and knowledge sharing.



Looking Ahead

Potential Impact Capacity

The deployment and immediate positive outcomes of the project is but a small part of what C-CAMP envisages the overall impact to be. A continued and exponential impact over the lifetime of the devices due to the capacity created through this project is expected. The potential impact over the lifetime of the product is given in the following infographics. While the project duration is 6 months, due to the rise in cases in the third wave recently and the uncertainty of the COVID-19 pandemic - vaccinations and immunization efforts can be sustained through technologies like Emvolio.



*Conservative estimate for heavy usage at average ambient temperature of 35 °C for 14 hours of cooling per outreach session

Phase 2 | +150 Emvolio Active Vaccine Carriers (CSR-supported) are approved for deployment in Assam to scale state-wide coverage and strengthen public health infrastructure.



Impact	Estimated number of hours of cooling for vaccines during project (6 months)	Estimated number of hours of cooling for vaccines during product lifetime (5 years)
Hours of cooling capacity created in the field by 1 device*	2016+	20,160+
Collective hours of cooling capacity created in the field by 50 devices*	100,800+	1,008,000+

*Estimated for heavy usage of 24 outreach sessions a month at an average ambient temperature of 35 °C for 14 hours of use per session, though it can hold temperature for 16+ hours in the field, vaccination sessions are currently held only for 6-8 hours in the field. (It has been tested to maintain 5 °C temperature even at a maximum ambient temperature

of 50 °C)

These are conservative estimates and the numbers are expected to be 1.5 times higher when operated moderately for 15 outreach sessions a month at an average ambient temperature of 25 °C for 14 hours of use per session, even extending product life from 5 to 7 years. The vaccine carrier can easily provide up to 24-28 hours of cooling in the field at average ambient temperatures of 25 °C and even more so as ambient temperatures dip.

Average Ambient Temperature	25 °C	35 °C
Passive Vaccine Carrier (Cooling In hours)	6	6
Emvolio Active Vaccine Carrier (Average hours of cooling*)	18	12
Vaccine Life Extended over Passive carriers	303%	196%

*Over 5 years of Usage

Vaccine life gets a boost exponentially at over 300% when Emvolio active vaccine carriers are utilised in the field at average ambient temperatures of 25 °C for over 5 years and extended by over 150% when used in the field at average ambient temperatures of 35 °C for over 5 years. Current immunization schedules do not allow for the complete potential of the device to be experience. Factors like vaccine hesitancy in certain parts of the county also contribute to the low turnout of vaccinations during outreach sessions. However, maternal - childcare initiatives can greatly be benefitted with a portable, intelligent active vaccine carrier.



Emvolio's Vaccine Surveillance Model

Emvolio vaccine carrier's key feature is the MyEmvolio supporting software – Emvolio's IoT enabled - data **tracking** dashboard and **on-device display of temperature** and other indicators addresses challenges of vaccine potency and efficacy, enabling ANMs to be better informed while on the field. MyEmvolio Dashboard for monitoring and tracking activity in the field by NHM Director, Director of Immunization, State Cold Chain Officer, District Program Managers and receiving alerts on various field required characteristics is compatible for integrating with eVIN platform in the future.

The Need |

<u>Traceability:</u> The lack of a streamlined vaccine delivery and management system makes it challenging to trace the trajectory of vaccines along the value chain, often resulting in erroneous administration of vaccines (expired vial, wrong drug, counterfeit/recalled products, etc.), which is a threat to public health. Further, recipients are often unable to keep track of their vaccine schedules, due to human error in registering data.

Inventory Management: Current inventory management systems used by vaccine store managers often compromise on vaccine efficacy and operational efficiency because they are not integrated with vaccine administration data. For example, store managers often maintain a greater-than-optimal stock, which increases the likelihood of compromised efficacy due to external factors such as power outages, expiry, etc.

Roadmap |

Blackfrog's goal is to develop an Advanced Immunization Management System (AIMS), which will enable sophisticated networking and data management capabilities, which in turn contribute to enhancing immunization coverage, traceability, and inventory management. Blackfrog's team aim to achieve this by integrating AIMS with the Government of India's Electronic Vaccine Intelligence Network (eVIN) portal, expanding the latter's capabilities beyond cold-chain management, to systemic immunization management. Further, the goal is to build an immunization database that feeds inputs back to the system, with the aim of continuous refinement.

Target Beneficiaries |

1. Vaccine store managers: Inefficiencies and losses are minimized.

2. Healthcare providers: Vaccine delivery and management processes are significantly simplified, reducing the margin of error.

3. Recipients: Simplified processes and reduced margin of error lead to higher standards of safety.

It would enable efficient delivery and management of vaccines (and biologicals for testing), reducing the overall burden on the public healthcare ecosystem.






Meeting SD3 goals through SD7 | Energy Model

Emvolio as a **solar powered**, **battery-operated** device provides a critical **health energy nexus** much required in the remote regions with intermittent power supply and can operate as a standalone refrigerator at a lower power consumption, reducing the need for ILRs and larger refrigeration units in Public Health Centers & sub-centres (*Currently being used in that manner as per the need in Fakirganj Model Hospital, Dhubri District, Assam*).

While there are plenty of solutions available for the areas with at least partial access to electricity, the vaccine storage and transportation for off-grid areas remains challenging. According to **Assam's State Cold Chain Officer**, there are thousands health posts in remote off-grid areas. The big challenges are: the reliable long-term storage devices that can keep vaccines within safe temperature range; and the logistics of ice and vaccines to support both vaccine distribution and outreach, **accessing communities in very-hard-to-reach areas**.

For Blackfrog's Emvolio, a 100W solar panel is sufficient to power the system with ample margin. The team's technical advisors are in the process of exploring compatibility with portable solar carriers, ensuring even further increase in cooling hours provided on the field.

SELCO Foundation, a pioneer and key enabler for off-the-grid, resilient and distributed renewable energy systems, is exploring the benefit to cost and energy via active carriers like Emvolio. **The current project is ongoing.**



Source: SELCO Foundation, Bangalore, India (2021)



Model for Scaling and Deployment of healthcare technology |

Assessing Emvólio Active Vaccine Carrier's Capacity for Impact | Proposed Model for Dhubri District



It is vital to the nation to upgrade healthcare infrastructure through deploying cutting edge healthcare innovations at scale to ensure the continuing evolution and transformation of the healthcare sector that will enable better healthcare, more affordable care and save lives.

The healthcare sector is highly regulated at state and national levels. Health infrastructure in India is largely publicly funded, and to ensure that the technologies reach the maximum number of people from excluded communities, geographies, and socio-economic background it is vital to work with the government sector for meaningful and lasting impact.

While effective, the healthcare system is a challenge to deal with for smaller companies, startups and even philanthropic agencies that aim to carry out positive interventions. This is where there is a need for a district-level and a country-wide model, with the relevant expertise to deploy and scale the model.

The institutional frameworks of cold-chain and healthcare are vast and only change very slowly over years. The pace at which healthcare innovations need to be deployed is very fast. The faster technologies are deployed, more lives are saved, and more people live healthy lives. Thus, while policy changes and systemic changes will take place in due course, the need to deploy quickly within the system is necessary to enable policy changes and this has been further highlighted by the COVID-19 pandemic.




To deploy quickly there is a strong need for:

- 1. Strong partnerships and network across the country
- 2. Experience in dealing with healthcare stakeholders
- 3. Experience in project management
- 4. Understanding of the healthcare scenario in terms of need, administration, and regulation
- 5. Access to the latest cutting-edge innovations and expertise to gauge their effectivity
- 6. A strong institution with ties to leading scientific and industrial offices of the nation

It is through these strengths that the C-CAMP team has created a model for technological deployment at scale. This is done with in-house protocols and an experienced team that will ensure a project is deployed despite several challenges that is presented by the ecosystem and value-chain.

Refer more details Page 8 – <u>Assam Deployment Model</u> Page 19 – <u>Deployment Report</u> Page 27 – <u>Technology Adoption</u> Page 28 - <u>Learnings</u>







Capacity Building

DISTRICT	South Salmara Mancachar	Dhu	ubri	Μ	ajuli		
Name of Public Health Centre	South Salmara PHC	Medartary S/D	Fakirganj Hospital	Ratanpur Miri PHC	Karatipar, Kamalabari PHC		
Total Trained ANMs / MPWs at site PHC and connected Sub-Centers			3	6	6		
Number of ANMs / MPWs trained for Emvolio	6	3	2	7	6		
Percentage of CCTs & CCHs trained for Emvolio*	100%	33	%	10	00%		
Total District Capacity for ANMs / MPWs for Emvolio**	76	42	28	9	73		

***Percentage of CCTs & CCHs trained for Emvolio –** Each district has 1 – 2 Cold-Chain Technicians and each PHC has minimum 1 cold-chain handler. This is the number of CCTs / CCHs per site that received training directly from the technology partner during deployment as part of the master-training plan, for the 6 selected districts.

**** Total District Capacity for ANMs / MPWs for Emvolio -** This includes the total number of ANMs, additional ANMs and MPWs available per district who can receive training and utilize Emvolio based on work shifts, outreach sessions and ease of portability of the device. The number of healthcare workers who initially received training from the cold-chain technicians and remote support from the technology partner during deployment can compound easily with the current capacity building plan.



DISTRICT	Karbi	Anglong	Dima Ho	asao	So	nitpur	
Name of the Centre	Dhansiri PHC	Chowkihola PHC	Diyungmukh PHC	Gunjung PHC	Dhekiajuli BPHC	Jamugurihat SHC	
Total Trained ANMs / MPWs at site PHC and connected Sub- Centers	10	4	13	17	87	26	
Percentage of CCTs & CCHs trained for Emvolio		100%	100%	6	67%		
Number of ANMs / MPWs trained for Emvolio*	10	4	7	8	26	24	
TotalDistrictCapacity for ANMs /MPWs for Emvolio**		243	173		;	357	

*Percentage of CCTs & CCHs trained for Emvolio – Each district has 1 – 2 Cold-Chain Technicians and each PHC has minimum 1 cold-chain handler. This is the number of CCTs / CCHs per site that received training directly from the technology partner during deployment as part of the mastertraining plan, for the 6 selected districts.

**** Total District Capacity for ANMs / MPWs for Emvolio** - This includes the total number of ANMs, additional ANMs and MPWs available per district who can receive training and utilize Emvolio based on work shifts, outreach sessions and ease of portability of the device. The number of healthcare workers who initially received training from the cold-chain technicians and remote support from the technology partner during deployment can compound easily with the current capacity building plan.



DISTRICT	Dh	ubri	Sonitpur			
Name of the Centre	Medartary	Fakirganj Hospital	Dhekiajuli	Jamugurihat		
Population & Vaccination Details						
In this district, what is the scale of vaccine						
hesitancy	3	2	3	3		
(Rate from 1 - lowest to 10 - highest)						
On an average, how many people						
administered COVID-19 vaccines using	100	60	100	100		
passive carriers, per day?						
On an average, how many children given	20	20	00	00		
RI with passive carriers, per day?	30	30	90	22		
Type of vaccinations being given at centre	COVID, RI	COVID, RI, JE	COVID, RI, JE	COVID, RI, JE		
Total no. of doses administered by PHC –	Nov -1987	Nov - 3728	Nov - 900	Nov -199		
COVID-19 (Nov-Dec)	Dec -1183	Dec - 3156	Dec - 697	Dec - 100		
Total no. of doses administered by PHC –		Nov 356	Nov - 101	Nov - 42		
RI (Nov-Dec)	Nov - 26	Dec 183	Dec - 83	Dec - 21		
No. of COVID-19 vaccinations with Emvolio	659	2455	298	42		
Monthly Coverage with Emvolio	56%	78%	43%	42%		
Per Day Average COVID-19 doses	120	129	50	14		
administered using Emvolio	132	127	50	14		
No. of COVID-19 sessions completed with	E	19		3		
Emvolio	5	17	6	3		
No. of RI sessions with Emvolio	16	36	0	152		
No. of JE sessions with Emvolio	-	5	-	30		



Technology Adoption & Monitoring Record Samples

HC Name, District	Medartary SI), Dhul	bri													
Schedule/Program																
hat is the weekly schedule for Routine imunizations?	Wednesday				I											
<pre>/hat is the weekly schedule for COVID-19 accinations?</pre>	Everyday															
l administered here	No															
ovishield or Covaxin administered here	Covishield															
Cold Chain Equipment Details																
ention PHCs & SCs ANM connected to	Medartary SI) / Nay	/aparo	wa SC												
ow many iceboxes are being used currently in ePHCs/SCs?	2 Medartary	+ 4 in \$	SC						4		No.					
ow many vials carried per ice box	15-25				TALO	District Name	Dhu	6351 (1	123411	-			to be fi	fied by Co	-	
earest cold chain storage point	Sirakuti CCP)				SHEET		5	12	Others		No. of	No. of vials	No. of	Dosage Quantity (51/m)	
Population & Vaccination Details					it dose	Covaxin 2nd dose	RI Details	JE	Polio	(Please specify)	Total	vials given	(reusable)	wasted vials	(5L/6L) 20L)	
n an average, how many people given RI before mvolio, per day/week?	30/day				000	0 0 0	0	0 0 0	0 0	0	0	6 13 10	000	0 0	63 132 100	
on an average, how many people administered OVID-19 vaccine before Emvolio, per day/week?	100/day				000	000	0 0 0	000	0 0 0	0 0	0 0 0	16 13 10	0 0	0 0 0	161 132 100	
n this district, what is the scale of vaccine esitancy (Rate from 1 - lowest to 10 - highest)	3				000	0 0 0	0000	0 0 0	000	0	0 0	17	0 0 0	0	170	
					0	0	0	0	0	0	0	4	0	0	70 90	
07-01-202 Khal	ida vihalles Aza	A 1	Lal	Fla	0	0	0	0	0	0	0	8	0	0	160	
05-01-2022 What the contract of the contract o	lida Mhalter	An an I	105 A	80	0	0	0	0	0	0	0	7.	0	0	72	
07-02-2022 Khal	da khalum Az		50	120 00	0	0	0	0	0	0	0	12	0	0	125	
18-01-2022 Khal	ida Khakir A	Lact 12	Ld	137 d	6	0	0	0	0	0	0	13	0	0	125	
17-01-2022 What 0-01-2022 What	Edg vehalunt		10	750	0	0	0	0	0	0	0	18	0	0	199	
1-01-22 Kh al	ida Khallen	As 6	d	116d	0	0	0	0	00	0	0	13	0	0	124	
2-01-22 Khali	da Khalten A	2000 1	od	Ind	0	U	d	0	0	0	0	13	0	0	132	
				810	0	0	0	0	0	8	0	9	0	0	20	
COVID-19 Vaccinations E	et Question	nnaire						1			Medar	tary, Dh	ubri			
Administered using Em	vo		6 d					1			medan	tary, Di				
	Any chal usage of	-		by you II	unde	rstand	ing the	No								
Covaxin 40 doses , Covishield 10 do	se Any feed	back or	n usin	a Emvoli) (weid	uht us	ade	Lisor		itself. U	nable t		mvolio i	n fiold	duo to	
Covaxin 70 doses , Covishield 40 do				3		,,	-3-,	weig		itsell. U	nable t	0 use L		in neiu	uue to	
Covishield 20 doses, Covaxin 60 do	se															
Covishield 60 doses, Covaxin 110 do	56					cod in			ondition							
		main i	iccupe	challonc:		ialiv ta	What are main issues/challenges usually faced in the field during your duty?					in case of emergency, patients are brought on pair carts				
Covishield 70 doses, Covaxin 70 do	se the field			-	es usu	ally fa	coum						Helpful especially in areas where electricity supply is			
Covishield 70 doses, Covaxin 70 do Covishield 50 doses , Covaxin 80 do	se the field	during y	your d	luty?				(thela	a)	ecially in	areas	where e	electrici	tv supr	olv is po	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do	se the field se What is y	during y /our exp	your d perien	luty? ice with t	is nev	v vacci	ine	(thela Help	a) ful esp	ecially ir ary SD it						
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do	se What is y se carrier ?	during y /our exp Has it r	your d perien reduce	luty? ice with t ed work h	iis nev ours ?	v vacci Has it	ine	(thela Help like N for cl	a) ful esp vledarta harging	ary SD it as well	self. De as stor	evice ca rage pur	in be tal rposes.	ken to In sun	residen imers	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do	se What are se What is y se What is y carrier ? helped in ssue a if	during y /our exp Has it r n areas	your d perien reduce where	luty? ice with t ed work h e transpo	iis nev ours ? t & ele	v vacci Has it	ine	(thela Help like I for cl espe	a) ful esp vledarta harging cially, i	ary SD it	self. De as stor	evice ca rage pur	in be tal rposes.	ken to In sun	residen imers	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do	se what is y se What is y se what is y se arrier ? helped ir issue - if	during y /our exp Has it r h areas yes, ho	your d perien reduce where ow has	luty? ice with t ed work h e transpo s it been	iis nev ours ? t & ele nelpful	v vacci Has it ectricity ?	ine : / is an	(thela Help like I for cl espe	a) ful esp vledarta harging	ary SD it as well	self. De as stor	evice ca rage pur	in be tal rposes.	ken to In sun	residen imers	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 140 do	what are the field se What is y scarrier ? helped ir issue - if How mar PHC/sub	during y /our exp Has it r areas yes, ho yes, ho	your d perien reduce where ow has	luty? ice with t ed work h e transpo s it been	iis nev ours ? t & ele nelpful	v vacci Has it ectricity ?	ine : / is an	(thela Help like I for cl espe refrig	a) ful espo Medarta harging cially, i gerator	ary SD it as well ce melts	self. De as stor s, so En	evice ca rage pur nvolio w	in be tal rposes. /ill be su	ken to In sun uitable	residen nmers as a	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 140 do Covishield 70 doses; Covaxin 60 do	se What are the field se What is y carrier ? helped ir issue - if How mar PHC/sub se Who bog	during y /our exp Has it r a areas yes, ho yes, ho ny hour	your d perien reduce where ow has rs of el e?	luty? Ince with t ad work h a transpo s it been lectricity	iis nev ours ? t & ele nelpful isually	v vacci Has it ectricity ? availa	ine : / is an	(thela Help like I for cl espe refrig	a) ful espo Medarta harging cially, i gerator	ary SD it as well	self. De as stor s, so En	evice ca rage pur nvolio w	in be tal rposes. /ill be su	ken to In sun uitable	residen nmers as a	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do	se what are the field se What is y carrier ? helped ir issue - if How mar PHC/sub se Who bea se sub-cent	during y /our exp Has it r areas yes, ho yes, ho ny hour -centre	your d perien reduce where ow has rs of el e? sport o	luty? nce with t ed work h e transpo s it been lectricity cost from	iis nev ours ? t & ele nelpful isually 1) PH	v vacci Has it ectricity ? availa C to	ine ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	(thela Help like I for cl espe refrig	a) ful espo Medarta harging cially, i gerator	ary SD it as well ce melts	self. De as stor s, so En	evice ca rage pur nvolio w	in be tal rposes. /ill be su	ken to In sun uitable	residen nmers as a	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 100 do Covishield 80 doses; Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do Covishield 10 doses; Covaxin 20 do	se What are the field se What is y carrier ? helped ir issue - if How mar PHC/sub se Who bea sub-cent se centre	during y /our exp Has it r areas yes, ho yes, ho ny hour -centre	your d perien reduce where ow has rs of el e? sport o	luty? nce with t ed work h e transpo s it been lectricity cost from	iis nev ours ? t & ele nelpful isually 1) PH	v vacci Has it ectricity ? availa C to	ine ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	(theli Help like N for cl espe refrig No e	a) ful esp Medarta harging cially, i gerator	ary SD it as well ce melts	self. De as stor s, so En	evice ca rage pur nvolio w ged at A	in be tal rposes. /ill be su .NM's re	ken to In sun uitable	residen imers as a ce	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do Covishield 10 doses; Covaxin 20 do Covishield 50 doses; Covaxin 80 do	se what are the field se What is y carrier ? helped ir issue - if How mar PHC/sub se Who bea sub-cent centre	during y Has it r a areas yes, ho y hour -centre rs trans re 2) Su	your d perien reduce where ow has rs of el e? sport o ub-cer	luty? nee with t ed work h e transpo s it been lectricity cost from ntre to ou	iis nev ours ? t & ele nelpful isually 1) PH	v vacci Has it ectricity ? availa C to /comm	ine y is an ible at nunity	(theli Help like N for cl espe refrig No e	a) ful esp Medarta harging cially, i gerator	ary SD it ⊧as well ce melts y. Devic	self. De as stor s, so En	evice ca rage pur nvolio w ged at A	in be tal rposes. /ill be su .NM's re	ken to In sun uitable	residen imers as a ce	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 100 do Covishield 80 doses; Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do Covishield 10 doses; Covaxin 20 do Covishield 50 doses; Covaxin 80 do Covishield 30 doses; Covaxin 90 do	se What are the field se What is y carrier ? helped ir issue - if How mar PHC/sub se Who bea sub-cent se Does sor PHSC or	during y your exp Has it r a areas yes, ho yyes, ho y hour -centre irs trans re 2) Su meone	your d perien reduce where ow has rs of el ? sport o ub-cer bring	luty? Ince with t ed work h e transpo s it been lectricity cost from ntre to ou	t & ele nelpful isually 1) PH	v vacci Has it ectricity ? availa C to /comm	ine y is an ible at nunity e	(theli Help like N for cl espe refrig No e	a) ful esp Medarta harging cially, i gerator	ary SD it ⊧as well ce melts y. Devic	self. De as stor s, so En	evice ca rage pur nvolio w ged at A	in be tal rposes. /ill be su .NM's re	ken to In sun uitable	residen imers as a ce	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 140 do Covishield 80 doses; Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do Covishield 10 doses; Covaxin 20 do Covishield 50 doses; Covaxin 90 do Covishield 30 doses; Covaxin 90 do	se What are the field se What is y carrier ? helped ir issue - if How mar PHC/sub se Who bea sub-cent se Does sor PHSC or os storage f	during y your exp Has it r a reas yes, ho -centre -centre rs trans re 2) Su meone	your d perien reduce where ow has rs of el e? sport o ub-cer bring u have	luty? Ince with t ed work h e transpo s it been lectricity cost from htre to out	is new ours ? t & ele helpful isually 1) PH treach treach	v vacci Has it ectricity? availa C to /comm s to the	ine y is an ible at nunity e	Khela Help like N for cl espe refrig No e	a) ful esp vledarta harging ccially, i gerator lectricit	ary SD it ⊧as well ce melts y. Devic	self. De as stor s, so En e charg	evice ca rage pur nvolio w ged at A	in be tal rposes. /ill be su .NM's re	ken to In sun uitable	residen imers as a ce	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 100 do Covishield 80 doses; Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do Covishield 10 doses; Covaxin 20 do Covishield 50 doses; Covaxin 80 do Covishield 30 doses; Covaxin 90 do	se What are the field se What is y carrier ? helped in issue - if How man PHC/sub Se Who bea sub-cent se Does sor PHSC or os storage f OS Have you you could	during y your exp Has it r h areas yes, ho hy hour- -centre urs trans re 2) Su meone t do you acility to u used l d not ta	your d perien reduce where ow has ow has rs of el e? sport o ub-cer bring u have to colle Emvo	luty? Ince with t ed work h e transpo s it been lectricity cost from the vacci e to carry ect the vac lio as a re	iis nev ours ? t & ele nelpful isually 1) PH treach treach me vial Emvol ccines	v vacci Has it ectricity availa C to comm s to the s to the ator wh	ine y is an able at nunity e ne	(thela Help like N for cl espe refrig No e AVD AVD No. f inform	a) ful esp vedarta harging cially, i gerator lectricit payme brings But, AN med du	ary SD it as well ce melts <u>y. Devic</u>	e charg n DHS(I SD	evice ca rage pur nvolio w ged at A FW) / As	in be tai rposes. rill be su .NM's re shakarn	ken to In sun uitable esiden ni from Has be	residen nmers as a ce State	
Covishield 70 doses, Covaxin 70 do Covishield 50 doses, Covaxin 80 do Covishield 60 doses, Covaxin 240 do Covishield 80 doses, Covaxin 270 do Covishield 30 doses, Covaxin 270 do Covishield 50 doses, Covaxin 100 do Covishield 80 doses, Covaxin 140 do Covishield 80 doses; Covaxin 140 do Covishield 70 doses; Covaxin 60 do Covishield 60 doses; Covaxin 40 do Covishield 10 doses; Covaxin 20 do Covishield 50 doses; Covaxin 90 do Covishield 30 doses; Covaxin 90 do	what are the field se the field se What is y carrier ? helped in issue - if Dost How man PHC/sub Se Who bea sub-centre Se Does son PHSC or os storage f OS Have you	during y vour exp Has it r h areas yes, ho hy hour -centre irs trans re 2) Su meone do you acility tr u used d not ta unit?	your d perien reduce where ow has rs of el e? sport o ub-cer bring u have to colle Emvo ake the	luty? Ince with t ed work h e transpo s it been lectricity cost from htre to out the vaccio the vaccio to carry ect the va lio as a re e vaccine	is new ours ? t & ele nelpful isually 1) PH treach me vial Emvol ccines frigera	v vacci Has it ectricity? availa C to /comm s to the ator wh to the	ine y is an able at nunity e ne	AVD	a) ful esp vedarta harging cially, i gerator lectricit payme brings But, AN med du	ary SD it as well ce melts y. Devic ents from vials to IM enqu	e charg n DHS(I SD	evice ca rage pur nvolio w ged at A FW) / As	in be tai rposes. rill be su .NM's re shakarn	ken to In sun uitable esiden ni from Has be	residen nmers as a ce State	

Are you able to trust Emvolio for use in the field ?


Yes, it will be reliable but has not been used yet in the field




Device Monitoring

The MyEmvolio Software Platform

Emvolio vaccine carrier's key feature is the MyEmvolio supporting software for the IoT-enabled live location tracking and monitoring of temperature and battery statistics. This was demonstrated to the office of DHSFW, Guwahati, to enable remote monitoring and view device usage per device per district in real time, especially useful during outreach sessions.


















Outcomes | A snapshot

Field Deployment of Indigenous Technology	Through CCAMP's incubation and acceleration platform, an indigenous innovation for last-mile cold-chain (Blackfrog's Emvolio) was selected for rapid deployment in the public health sector. Blackfrog was selected based on their indepth understanding of last-mile cold chain challenges in India
Relevance of Technologies Beyond the Pandemic	 "Helpful especially in areas where electricity supply is poor like Medartary SD itself. Device can be taken to residence for charging as well as storage purposes. In summers especially, ice melts, so Emvolio will be suitable as a refrigerator." ANM, Medartary S/C, Dhubri Scaling of operations from COVID-19 to Maternal & Childcare Programmes, biological samples and storage options in the field
Dissemination of impact for technology scale-up and highlighting the catalysing role of DHSFW & HTPF	In working with DHSFW & HTPF, the teams have learned about additional areas of support needed and have begun working on solutions for the same. This includes collaboration for solar-enabled PHCs, improvement in remote monitoring through dashboard, inventory support, upgradation of backpacks for better weight distribution, revision of training protocol to address WHO standards.





Context relevant technology development	Feedback from the Assam deployment has helped with improving Blackfrog's next- generation cold-chain product and scaled R&D efforts to meet requirements on the ground. These efforts are being aligned directly to the needs of ANMs, CCHs, and other healthcare workers in public settings on the ground.	
Bringing indigenous technology and innovation to cold-chain practices	The site monitoring and beneficiary interviews show that there are challenges in adoption of an active carrier viz-a-vis the existing passive carriers. Behaviour modification is favoured by time and at the end of 3 months, there is a positive outlook towards acceptance of indigenous technology being fostered. This will help with the integration of new technologies in the public health sector in the future. The benefits and generation of real-world last- mile cold-chain data will help with further integration and adoption into the Indian healthcare system.	<image/>





Case Study

By C-CAMP Technology Impact Programme

Understanding the Cold-Chain System for the development of an Immunization & Vaccination Model for Improved Healthcare

> Vaccines—and lives—at risk Approximately 70 percent of the vaccines procured annually by UNICEF are freeze-sensitive, totaling \$70 million per year. Exposure of these freeze sensitive vaccines to extreme cold could result in a staggering loss of money and effort, and leave vaccinated patients unprotected from vaccine-preventable diseases.

PATH, WHO. Above Zero: Strategies to Prevent Vaccine Freezing. Seattle: PATH, WHO; 2013.

According to Ministry of Health and Family Welfare (MOHFW) India, Vaccine Management has an objective to maintain the safety and potency of vaccine during storage and transportation. The vaccines lose their potency if they are not stored or transported at the recommended temperature and condition. If vaccines are not stored safely (within recommended temp.), it may lead to Adverse Event Following Immunization (AEFI). Hence all attempts should be made to retain the safety of the vaccine, and maintaining the recommended temperature.

Checking for heat damage: The Vaccine Vial Monitor (VVM) is a label containing heat-sensitive material, which is placed on the vaccine vial to register cumulative heat exposure between the time period of exit from the manufacturing site till the time of use. The combined effects of time and temperature causes the inner square of the VVM to darken gradually and irreversibly. Before opening a vial, check the status of the VVM. Does a VVM measure vaccine potency? No, the VVM does not directly measure vaccine potency but it gives information about a major factor that affects potency, i.e., heat exposure over a period of time. The VVM does not, however, measure exposure to freezing that contributes to the degradation of freeze-sensitive vaccines

Freeze Damage: 1. Causes of freezing a. Improper storage in Ice lined refrigerator: b. Cold climates and ambient temperature is less than 0°C c. Storage and transport with non-conditioned frozen ice packs. d. Defective ILR. e. Untrained or improperly trained staff handling vaccine/cold chain. f. Incorrect thermostat adjustment (Handbook for Vaccine & Cold Chain Handlers, 2nd edition, India, 2016).





The development and introduction of a unique solution in cold-chain to address the above challenges and concerns in the field has been undertaken by many organisations and academic institutes over the decade. However, very few have been successful in building a solution that has the overarching aim of reducing as many potential problems in the field such as –

- Poor or no electrical supply
- Strict temperatures of 2 to 8 °C across drastic ambient temperatures
- Portability in difficult terrains
- Weatherproofing to meet the diverse climate across Indian regions
- Difficulty in end-user training and capacity building
- Efficient management through IoT -based technology
- Temperature monitoring without data loggers,
- Scaled-down routine and operating protocol for maintenance of vaccine carriers
- Capacity for multiple types of biological samples and specimens


The Emvolio Active Vaccine Carrier is one such technology that does so. The current scenario surrounding the COVID-19 pandemic has resulted in the rapid scale of technological solutions to address the growing needs. Under the above circumstances, C-CAMP, introduced Blackfrog Technologies to the State of Assam and Manipur with a deployment of 100 active vaccine carriers over a period of 6 months.


There have been challenges in deployment and adoption of a new disruptive technology in the last-mile process for the safe transportation and delivery of both COVID-19 vaccines and routine immunization vials. New ministry-approved protocols need to be developed for India to scale and grow in its vaccination and immunization efforts. Adoption of any new technology varies across cultures and communities based on multiple factors. Healthcare is a highly regulated field that requires behaviour modification practices to move the needle towards better health outcomes. This can be enabled through understanding, education and collaborative efforts across stakeholders in the public and private healthcare sectors. This is C-CAMP's goal, to provide access and affordable technology through its expertise to develop models for improved healthcare practices and standards.

The current deployment can generate evidence d can support proposals at a policy level for cold chain technology, there is a changing trend towards the recommendation and use of active portable refrigeration carriers for all vaccinations versus passive carriers. This recommendation for cold-chain technology is done globally by WHO, whose standards for are followed in India by the Ministry of Health. There is a strong focus on PQS product specifications for portable, active vaccine carriers over passive carriers. (WHO Performance, Quality and Safety (PQS) process prequalifies products and devices so that member states and UN purchasing agencies are assured of their suitability for use in immunization programs.) **Emvolio is designed as per WHO PQS standards and will be applicable for prequalification by February 2022 when the World Health Organisation commences prequalification applications.**



Comparing current protocols and SOPs with Emvolio Active Vaccine practices









Uses: To carry vaccine from last CCP to outreach sessions and bring back the open vials (Under the Open Vial Policy) from the session sites for storing & subsequent use.

How to pack a vaccine carrier

- → Confirm that there are no cracks in the walls of the vaccine carrier.
- → Take out the required number of ice packs from the deep freezer and wipe them dry. Keep them out side for conditioning before placing into carrier.
- \rightarrow Place four conditioned ice packs into the vaccine carrier along the sides.
- → Wrap vaccine vials and ampoules in thick paper (e.g. plain white paper) before putting in polythene bag so as to prevent them from touching the ice packs. This would also help in absorbing the moisture as accumulation of moisture would damage the labels on the vaccine vials.
- → Place the plastic bag in the centre away from the ice packs. This will prevent labels from peeling off from the vials.
- → Place foam pad on top of ice packs
- → If more than one vaccine carrier is being carried for a single session site, keep the whole range of the vaccines required for the day's use in each carrier so that only one carrier is opened at a time.

Some useful Do's and Don'ts:

- → Ensure that some ice is present in the ice packs while conducting immunization sessions.
- → Ensure collection of vaccines in the vaccine carrier on the session day only.
- → Avoid dropping, knocking or sitting on the Vaccine Carrier.
- → Do not leave the vaccine carrier in the sunlight.

→ Close the lid tight & securely.

Handbook for Vaccine & Cold Chain Handlers, India 2016 (2nd edition) Developed jointly by Unicel India Country Office and National Cold Chain as Vaccine Management Resource Centre (NCCVMRC), NIHFW for Ministry o Health & Family Welfare, Government of India unicef




- Switch on Emvolio Active Vaccine Carrier to begin active cooling
- 2. Wait for LED indicator on device to turn GREEN
- Collect vaccine vials and place vials in a plastic zip lock pouch carefully
- 4. Unlock the lid of Emvolio Active Vaccine Carrier
- 5. Place the zip lock pouch containing the vials inside the cooled chamber
- 6. Close the lid and lock before carrying

NOTE: Lid can remain unlocked during immunisation sessions, easy to open and close without compromising temperature inside Device can be kept in direct sunlight Do Not Obstruct / Block the lid or vent at the top of the device









> Bull World Health Organ. 2013 Dec 1;91(12):906-13. doi: 10.2471/BLT.13.119974. Epub 2013 Sep 9.

Frequent exposure to suboptimal temperatures in vaccine cold-chain system in India: results of temperature monitoring in 10 states

Manoj V Murhekar ¹, Srihari Dutta ², Ambujam Nair Kapoor ³, Sailaja Bitragunta ⁴, Raja Dodum ⁵, Pramit Ghosh ⁶, Karumanagounder Kolanda Swamy ⁷, Kalyanranjan Mukhopadhyay ⁸, Somorjit Ningombam ⁹, Kamlesh Parmar ¹⁰, Devegowda Ravishankar ¹¹, Balraj Singh ¹², Varsha Singh ¹³, Rajesh Sisodiya ¹⁴, Ramaratnam Subramanian ⁷, Tana Takum ⁵

Affiliations + expand

PMID: 24347729 PMCID: PMC3845272 DOI: 10.2471/BLT.13.119974

Findings: In state, regional and district vaccine stores and peripheral health facilities, respectively, the temperatures in the boxes exceeded 8 °C for 14.3%, 13.2%, 8.3% and 14.7% of their combined storage times and fell below 0 °C for 1.5%, 0.2%, 0.6% and 10.5% of these times. The boxes also spent about 18% and 7% of their combined times in transit at < 0 and > 8 °C, respectively. In shake tests conducted at the end of the study, two thirds of the vaccine vials in the boxes showed evidence of freezing.

Conclusion: While exposure to temperatures above 8 °C occurred at every level of vaccine storage, exposure to subzero temperatures was only frequent during vaccine storage at peripheral facilities and vaccine transportation. Systematic efforts are needed to improve temperature monitoring in the cold-chain system in India.





How can Emvolio Active Vaccine Carrier help in an emergency

Switch on Emvolio Active Vaccine Carrier



In 15 minutes it will be cooled to a preset temperature of 3°C

Carefully transfer 40-50 vaccine vials (if 10ml vial) from cold box or ILR and place it in Emvolio and transport to nearest cold chain point

Parameters		Ice Box	Emvólio
Peak Temperature (T ₁)		9.3°C	10.4°C
Temperature change brought Refrigeration (dT)	t about by	4.7	5.8
Time taken to reach 4.6°C (T₀) in minutes (dX)		35	22
Rate of cooling R = dT/dX		0.13429 °C/min	0.26364 °C/min
mprovement in rate of cooling = $(R_{Emv000} - R_{icebox})/1$ = $(0.26364 - 0.134)$			
	= 96.33%		

a rate of 96.33% faster than the icebox.

Phase 2 | To develop a comprehensive protocol for Emvolio active carriers for use in immunisation and vaccination activities, based on gap analysis and technology feedback from Assam, to meet the goal of reducing vaccine wastage and improving health outcomes